五聚素 3 作为急性阑尾炎诊断生物标志物的效用：系统评价和荟萃分析。

Utility of Pentraxin-3 as a biomarker for diagnosis of acute appendicitis: a systematic review and meta-analysis.

机构信息

Department of Pediatric Surgery, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India.

Department of Pediatric Surgery, Turku University Hospital and University of Turku, Turku, Finland.

出版信息

Pediatr Surg Int. 2022 Aug;38(8):1105-1112. doi: 10.1007/s00383-022-05149-4. Epub 2022 Jun 15.

PURPOSE

To systematically summarize all relevant data and to define the current evidence on the utility of Pentraxin-3 (PTX3) as a biomarker for acute appendicitis (AA) in children.

METHODS

This review was conducted in accordance with the PRISMA guidelines. PubMed, Embase, Scopus, and Web of Science databases were systematically searched for studies comparing the levels of PTX3 in patients with AA vs healthy controls or non-specific abdominal pain (NSAP). Mean differences were calculated for all outcomes and the inverse variance method was used for weighted mean difference. The methodological quality of the included studies was assessed using the Downs and Black scale.

RESULTS

Five comparative studies were included. Significantly elevated levels of PTX3 in cases with AA vs healthy controls (WMD: 9.56, 95% CI 7.24-11.88, p < 0.00001), and patients with AA vs NSAP (WMD: 8.05, 95% CI 6.81-9.29, p < 0.00001) were demonstrated. Similarly, in separate meta-analyses, the levels of PTX3 were significantly elevated in children with AA vs healthy controls (WMD: 11.18, 95% CI 10.03-12.34, p < 0.00001), and children with AA vs NSAP (WMD: 8.35, 95% CI 6.88-9.82, p < 0.00001).

CONCLUSIONS

PTX3-levels are elevated in AA, but differentiation between perforated and non-perforated appendicitis demands other methods.

目的

系统总结所有相关数据，并确定 Pentraxin-3（PTX3）作为儿童急性阑尾炎（AA）生物标志物的效用的现有证据。

方法

本综述按照 PRISMA 指南进行。系统检索了 PubMed、Embase、Scopus 和 Web of Science 数据库，以比较 AA 患者与健康对照或非特异性腹痛（NSAP）患者的 PTX3 水平的研究。对所有结局计算了均数差值，并使用Inverse variance 法进行加权均数差的计算。使用 Downs 和 Black 量表评估纳入研究的方法学质量。

结果

纳入了 5 项比较性研究。AA 患者与健康对照组（WMD：9.56，95%CI 7.24-11.88，p<0.00001）以及 AA 患者与 NSAP 患者（WMD：8.05，95%CI 6.81-9.29，p<0.00001）的 PTX3 水平显著升高。同样，在单独的荟萃分析中，AA 患儿与健康对照组（WMD：11.18，95%CI 10.03-12.34，p<0.00001）以及 AA 患儿与 NSAP 患儿（WMD：8.35，95%CI 6.88-9.82，p<0.00001）的 PTX3 水平也显著升高。